Eupraxia Pharmaceuticals appoints new technical operations heads, co-founder Malone steps down

Management
โดย RTTNews·Read original
Summary · why it matters

Eupraxia Pharmaceuticals announced leadership changes to support its planned clinical and commercial growth. Jeff Millard was appointed Executive Vice President of Technical Operations effective July 13, 2026, bringing over 25 years of experience from Ensysce Biosciences, Microbion Corporation, and Cascadian Therapeutics. Alex Therien, who joined in November 2025, became Executive Vice President of Research and Development, with more than 20 years of biopharmaceutical experience from Generate Biomedicines, Eikon Therapeutics, and Merck. Co-founder Amanda Malone stepped down as Chief Scientific and Operating Officer on July 10, 2026, after overseeing two pivotal Phase 2 osteoarthritis studies. The company also completed its operational transition from Victoria, British Columbia, to Vancouver and Seattle, establishing a cross-border two-hub structure with key leadership based in Seattle.

Impact on stocks 7

Biotech & Genomic Medicine▲ · 4 stocks
Materials▲ · 1 stocks
Health Care▲ · 1 stocks
Critical Materials & Supply Chain▲ · 1 stocks

Off-coverage companies 2

Generate BiomedicinesPrivate± Mixed
relevance

Microbion CorporationPrivate± Mixed
relevance

© 2026 MarketDXNews